secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001104659-24-114773
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode gets Nasdaq extension to regain compliance; Public Reprimand issued
-----------------------------------------------------------------------------

- Nasdaq Hearings Panel granted extension to comply with Bid Price Rule 5550(a)(2), Equity Rule 5550(b), and Shareholder Approval Rule 5635(d).
- Company issued 10M shares at $0.30 on July 22, 2024, a 62% discount to the $0.7925 minimum price, without shareholder approval.
- Panel issued a Public Reprimand Letter for the unauthorized issuance; company remains listed subject to conditions.
- TransCode must demonstrate compliance with listing rules within the extension period or face delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924114773/0001104659-24-114773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924114773/tm2427567d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-114773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer